319 related articles for article (PubMed ID: 23670191)
1. Propofol inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1.
Yang SC; Chung PJ; Ho CM; Kuo CY; Hung MF; Huang YT; Chang WY; Chang YW; Chan KH; Hwang TL
J Immunol; 2013 Jun; 190(12):6511-9. PubMed ID: 23670191
[TBL] [Abstract][Full Text] [Related]
2. Bioactive secondary metabolites of a marine Bacillus sp. inhibit superoxide generation and elastase release in human neutrophils by blocking formyl peptide receptor 1.
Yang SC; Lin CF; Chang WY; Kuo J; Huang YT; Chung PJ; Hwang TL
Molecules; 2013 Jun; 18(6):6455-68. PubMed ID: 23736784
[TBL] [Abstract][Full Text] [Related]
3. Propofol inhibits endogenous formyl peptide-induced neutrophil activation and alleviates lung injury.
Chen CY; Tsai YF; Huang WJ; Chang SH; Hwang TL
Free Radic Biol Med; 2018 Dec; 129():372-382. PubMed ID: 30312762
[TBL] [Abstract][Full Text] [Related]
4. Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1.
Liu FC; Yu HP; Syu YT; Fang JY; Lin CF; Chang SH; Lee YT; Hwang TL
Sci Rep; 2017 Jul; 7(1):6718. PubMed ID: 28751674
[TBL] [Abstract][Full Text] [Related]
5. Garcinia Multiflora Inhibits FPR1-Mediated Neutrophil Activation and Protects Against Acute Lung Injury.
Tsai YF; Yang SC; Chang WY; Chen JJ; Chen CY; Chang SH; Hwang TL
Cell Physiol Biochem; 2018; 51(6):2776-2793. PubMed ID: 30562761
[TBL] [Abstract][Full Text] [Related]
6. Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1.
Yang SC; Chang SH; Hsieh PW; Huang YT; Ho CM; Tsai YF; Hwang TL
Free Radic Biol Med; 2017 May; 106():254-269. PubMed ID: 28232203
[TBL] [Abstract][Full Text] [Related]
7. Functional selective FPR1 signaling in favor of an activation of the neutrophil superoxide generating NOX2 complex.
Lind S; Dahlgren C; Holmdahl R; Olofsson P; Forsman H
J Leukoc Biol; 2021 Jun; 109(6):1105-1120. PubMed ID: 33040403
[TBL] [Abstract][Full Text] [Related]
8. Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo.
Korinek M; Hsieh PS; Chen YL; Hsieh PW; Chang SH; Wu YH; Hwang TL
Biochem Pharmacol; 2021 Aug; 190():114596. PubMed ID: 33964283
[TBL] [Abstract][Full Text] [Related]
9. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
10. The potential impacts of formyl peptide receptor 1 in inflammatory diseases.
Yang SC; Hwang TL
Front Biosci (Elite Ed); 2016 Jun; 8(3):436-49. PubMed ID: 27100350
[TBL] [Abstract][Full Text] [Related]
11. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
12. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
Kretschmer D; Rautenberg M; Linke D; Peschel A
J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
[TBL] [Abstract][Full Text] [Related]
13. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.
Yan P; Nanamori M; Sun M; Zhou C; Cheng N; Li N; Zheng W; Xiao L; Xie X; Ye RD; Wang MW
J Immunol; 2006 Nov; 177(10):7050-8. PubMed ID: 17082621
[TBL] [Abstract][Full Text] [Related]
14. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
15. The proteolytically stable peptidomimetic Pam-(Lys-βNSpe)6-NH2 selectively inhibits human neutrophil activation via formyl peptide receptor 2.
Skovbakke SL; Heegaard PM; Larsen CJ; Franzyk H; Forsman H; Dahlgren C
Biochem Pharmacol; 2015 Jan; 93(2):182-95. PubMed ID: 25462815
[TBL] [Abstract][Full Text] [Related]
16. Targeting formyl peptide receptor 1 with anteiso-C13-surfactin for neutrophil-dominant acute respiratory distress syndrome.
Yang SC; Wang YH; Ho CM; Tsai YF; Sung PJ; Lin TE; Hwang TL
Br J Pharmacol; 2023 Aug; 180(16):2120-2139. PubMed ID: 36929355
[TBL] [Abstract][Full Text] [Related]
17. AZ2158 is a more potent formyl peptide receptor 1 inhibitor than the commonly used peptide antagonists in abolishing neutrophil chemotaxis.
Forsman H; Wu Y; Mårtensson J; Björkman L; Granberg KL; Dahlgren C; Sundqvist M
Biochem Pharmacol; 2023 May; 211():115529. PubMed ID: 37004778
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.
Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT
Int Immunopharmacol; 2016 Aug; 37():43-58. PubMed ID: 26382576
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages.
Gemperle C; Schmid M; Herova M; Marti-Jaun J; Wuest SJ; Loretz C; Hersberger M
PLoS One; 2012; 7(11):e50195. PubMed ID: 23185575
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of a bifunctional ligand of the formyl peptide receptor1 fused to the myc epitope.
Charest-Morin X; Roy C; Fernandes MJ; Marceau F
Int Immunopharmacol; 2015 Mar; 25(1):229-34. PubMed ID: 25681283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]